Neuroendocrine tumour (NET), Secondary cancers
Results
Phase 3
This trial compared everolimus and a type of internal radiotherapy called 177Lu-edotreotide for people with a neuroendocrine tumour (NET).
It was for people with a type of called a gastroenteropancreatic neuroendocrine tumour, or GEP-NET. This means that it started in part of the digestive system such as the stomach, bowel or pancreas.
People in the UK could join between 2018 and 2022. The team presented results at several conferences in 2025. They plan to publish the results in a medical journal.
Recruitment start: 18 April 2018
Recruitment end: 30 April 2022
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Prof Dr Shaunak Navalkissoor
ITM Solucin
Last reviewed: 02 Dec 2025
CRUK internal database number: 15510
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
Search our clinical trials database for all cancer trials and studies recruiting in the UK.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
